Introduction Targeted radionuclide therapy with Lutetium-177 labelled PSMA (177Lu-PSMA) has emerged as a leading option for metastatic castration-resistant prostate cancer (mCRPC). Traditional dosimetry often relies on multiple time-point imaging to capture radiopharmaceutical pharmacokinetics, which can create a substantial imaging burden, workload, and costs. Single time-point (STP) dosimetry, particularly at about 48 hours post-administration, offers a…